RhumbLine Advisers’s MaxCyte MXCT Stock Holding History
Bought
Maintained
Sold
Other funds holding MXCT
CFM
VP
VCM
MA
BFM
RhumbLine Advisers's MXCT Position: Q1 2026 in Review
RhumbLine Advisers reduced its MaxCyte (MXCT) stake by 11% in Q1 2026, selling an estimated $14.8K and leaving 122,294 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3463.
RhumbLine Advisers first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $955K in Q4 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.
- RhumbLine Advisers held 122,294 shares of MaxCyte worth $85.8K as of Q1 2026.
- RhumbLine Advisers sold 15,839 MaxCyte shares in Q1 2026, an estimated $14.8K.
- MaxCyte made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3463 holding.
- RhumbLine Advisers first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
- RhumbLine Advisers's MaxCyte position peaked at $955K in Q4 2021.
- 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.